abrdn plc Has $25.02 Million Holdings in IQVIA Holdings Inc. (NYSE:IQV)

abrdn plc grew its stake in IQVIA Holdings Inc. (NYSE:IQV) by 138.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 108,151 shares of the medical research company’s stock after buying an additional 62,776 shares during the period. abrdn plc owned approximately 0.06% of IQVIA worth $25,024,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in IQV. AdvisorNet Financial Inc lifted its position in shares of IQVIA by 327.6% in the fourth quarter. AdvisorNet Financial Inc now owns 124 shares of the medical research company’s stock worth $29,000 after buying an additional 95 shares during the last quarter. BKM Wealth Management LLC acquired a new stake in shares of IQVIA in the fourth quarter worth about $32,000. Activest Wealth Management bought a new position in shares of IQVIA in the fourth quarter worth about $35,000. CVA Family Office LLC bought a new position in shares of IQVIA in the fourth quarter worth about $43,000. Finally, CoreFirst Bank & Trust bought a new position in shares of IQVIA in the third quarter worth about $44,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

Analysts Set New Price Targets

IQV has been the topic of a number of recent analyst reports. SVB Leerink initiated coverage on IQVIA in a research note on Monday, February 26th. They issued an “outperform” rating and a $290.00 price objective on the stock. BTIG Research initiated coverage on IQVIA in a research note on Tuesday, February 13th. They issued a “buy” rating and a $285.00 price objective on the stock. Barclays lifted their price objective on IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Leerink Partnrs reiterated an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. Finally, Robert W. Baird lifted their price objective on IQVIA from $226.00 to $251.00 and gave the stock a “neutral” rating in a research note on Thursday, February 15th. Three research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $256.80.

IQVIA Trading Up 3.2 %

Shares of IQV opened at $238.74 on Wednesday. IQVIA Holdings Inc. has a 1 year low of $167.42 and a 1 year high of $261.73. The company has a current ratio of 0.86, a quick ratio of 0.86 and a debt-to-equity ratio of 2.12. The stock has a 50 day simple moving average of $245.55 and a 200-day simple moving average of $222.56. The stock has a market cap of $43.33 billion, a PE ratio of 32.75, a PEG ratio of 2.24 and a beta of 1.50.

IQVIA (NYSE:IQV) last issued its earnings results on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.82 by $0.02. The business had revenue of $3.87 billion during the quarter, compared to analysts’ expectations of $3.80 billion. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. IQVIA’s quarterly revenue was up 3.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $2.54 EPS. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.

Insider Buying and Selling

In related news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the sale, the insider now directly owns 5,251 shares in the company, valued at approximately $1,313,642.67. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In other IQVIA news, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total value of $2,153,213.19. Following the transaction, the insider now directly owns 5,251 shares in the company, valued at approximately $1,313,642.67. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Ari Bousbib sold 31,678 shares of the stock in a transaction on Friday, March 1st. The shares were sold at an average price of $250.53, for a total value of $7,936,289.34. Following the completion of the transaction, the insider now owns 796,752 shares in the company, valued at $199,610,278.56. The disclosure for this sale can be found here. Insiders have sold a total of 41,285 shares of company stock worth $10,331,003 in the last three months. Insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.